Global stock

NASDAQUSD

Biogen Inc.

BIIB

AI analysis and articles are in Czech.

§ Financial healthLong-term stability

51/ 100

Overall score·BIIB

Current price

249.85USD

26/10/2026

P/E, P/B

Valuation

Neutral

Rates whether the stock is cheap or expensive relative to its history and sector. A score above 60 suggests the stock trades below its estimated intrinsic value.

Tracks:P/E · P/B · FCF yield · sector

Aktivum má vysoké P/E a nízké forward P/E, což naznačuje nadhodnocení na základě současných valuací, avšak růstové ukazatele jsou slabé, zatímco stabilita je vysoká. Největší slabinou je nízká ziskovost a záporný růst zisku, zatímco momentum a nálada trhu jsou průměrné.

§ Outlook vs S&P 500Next 12 months

About the same

Estimated chance of beating the index: about 47%

8 of 8 inputs

NoProbably notSameProbably yesYes

A model estimate from current values. The result may change with new data; it is not a price target or an investment recommendation.

§ Metrics summary

A quick look at Biogen Inc. (BIIB) combining financial health, the short-term signal, valuation, DCF, management quality and operating metrics. It is analytical context, not a recommendation to buy or sell.

51/100

The overall score is based mainly on long-term fundamentals, complemented by the current signal and the available qualitative rating of the company.

59/100

Slightly positive signal based on current news, price action and the economy.

54/100

A lower score means the stock is expensive relative to the company's earnings and assets.

16% above fair value

An estimate of what the stock should be worth based on the company's future cash.

+3%

How fast the company's revenue grows year on year.

40/100

How much the company earns from each unit of revenue and from invested capital.

80/100

Debt level, share-price volatility and how resilient the company is in bad times.

70/100

AI estimate of management quality, execution and capital allocation.

60/100

AI estimate of the company's durable competitive advantage.

§ Context and events

Management

Christopher A. Viehbacher je prezident, CEO a člen představenstva; Robin C. Kramer působí jako výkonná viceprezidentka a CFO. Strategie společnosti zahrnuje rozvoj portfolia neurologických a vzácných onemocnění a posilování novějších přípravků, včetně léčby Alzheimerovy choroby.

Articles about Biogen Inc., in Czech (1)

Biogen získává průlomové označení FDA pro novou terapii SMA Salanersen

Biogen oznámil, že jeho nová generace léčby spinální muskulární atrofie (SMA), Salanersen, získala od FDA označení 'Breakthrough Therapy'. Tato značka urychlí vývoj a schvalovací proces, což může výrazně urychlit dostupnost této inovativní terapie pacientům.

5 June 2026· 2 min

§ Upcoming results

28 October 2026

Tomorrow

Earnings

Earnings = quarterly financial results (revenue and profit). Companies publish them every three months and the share price often reacts strongly.

§ Frequently asked questions

What is Biogen Inc. (BIIB)?

Biogen Inc. (BIIB) is a global stock traded on NASDAQ. Sector: Healthcare. We track it daily — scoring news sentiment, the short-term outlook and long-term stability on a 0–100 scale.

What is the Biogen Inc. price today?

As of 26 October 2026, Biogen Inc. trades at about 249.85 USD per unit. We update the price daily from public market data. Intraday moves can differ significantly — always check the final price with your broker.

How to buy Biogen Inc.?

Through regulated online brokers such as Degiro, XTB, Trading 212 or Interactive Brokers. Shares trade in USD or EUR — most brokers convert your currency automatically. FinSignal does not operate any of these platforms and charges no commission — the overview is only a signpost.

Does Biogen Inc. pay a dividend?

Biogen Inc. either pays no dividend at the moment or we have no reliable data on it. Many growth companies prefer reinvesting profit to paying dividends — check the current policy in the company's investor relations materials.

Is Biogen Inc. a good investment in 2026?

Our AI signal currently rates Biogen Inc. as slightly positive (score 59/100). Financial health comes out at 51/100, so beyond short-term news it is worth watching the valuation, growth, profitability and stability of the company. The DCF model currently puts the price about 16 % above its model fair value. FinSignal is not an investment adviser licensed under Czech Act No. 256/2004 Coll. — signals are analytical input, not a recommendation to buy or sell. You make every decision at your own risk.

§ More global stocks

Microsoft Corporation

MSFThealth 73/100

§ How to buy Biogen Inc.

You can buy shares through regulated online brokers available in the EU. They differ mainly in fees, app quality and which markets they cover.

Degiro
Dutch broker with low fees for passive investors. No account fee, trading in EUR and USD.
XTB
Polish broker with zero commission on stocks and ETFs up to EUR 100,000 a month. Own xStation platform.
Trading 212
Zero-commission broker with fractional shares from EUR 1 and automated investing (Pies). Suits beginners and regular investing.
Interactive Brokers
US broker for advanced investors. The widest choice of markets, low costs at larger volumes, a professional platform with a steeper learning curve.

FinSignal operates none of these platforms. We charge no commission on purchases.

Important: Signals are an analytical tool, not investment advice within the meaning of Czech Act No. 256/2004 Coll. Past performance does not guarantee future results. You make all decisions at your own risk.

§ Current signalShort-term mood

/ 100

● Slightly positive

Earnings tomorrow

On 28 October 2026 the company publishes its quarterly results. This period tends to bring large price moves.

News summary

Fresh news

Signal 27/10, 12:01

Biogen se připravuje na zveřejnění výsledků; potvrzení růstu produktů by podpořilo výhled, zatímco zklamání by mohlo oslabit současné momentum.

Růst ceny za 7 i 30 dní a vzestupný trend podporují krátkodobý výhled. RSI 71 a vysoká volatilita zvyšují riziko korekce; dlouhodobější obraz zůstává méně přesvědčivý.

Risks: Slabší výsledky nebo opatrný výhled mohou přerušit růstový trend a vyvolat korekci.

More about the signal

Růst ceny za 7 i 30 dní a vzestupný trend podporují krátkodobý výhled. RSI 71 a vysoká volatilita zvyšují riziko korekce; dlouhodobější obraz zůstává méně přesvědčivý.

Risks: Slabší výsledky nebo opatrný výhled mohou přerušit růstový trend a vyvolat korekci.

Signal history· 2

26/1021:0265 · Slightly positive
Před výsledky za 3. čtvrtletí se řeší, zda růstové produkty Biogenu povedou k překonání odhadů; potvrzené silné výsledky by podpořily výhled, zklamání jej může oslabit.
24/1019:0168 · Slightly positive
Biogen 23. října vzrostl o 5,3 % a zpráva z 22. října spojuje růst s navýšením cílové ceny BofA před relativně klidnými výsledky za 3. čtvrtletí; další růst by podpořilo potvrzení očekávání.

The full 90-day signal history is part of Premium.

Ask the AI

§ Model fair value (DCF)

Fairly valued16% above fair value

216.15

range 171.9 – 278.8

Current price

249.85 USD

26 Oct 26

PriceFair value range (DCF)UndervaluedOvervalued

What the calculation is based on

Model

216.15 USD

range 171.9 USD – 278.8 USD

: 3.0%
: 9.0%
: 13.41 USD

Růst FCF 3 % p.a. je konzervativní vzhledem k růstu tržeb 3 % a výraznému poklesu EPS, který zvyšuje nejistotu výhledu. Diskontní sazba 9 % zohledňuje rizika farmaceutického portfolia a vývoje nových léčiv, přestože uvedená beta je nízká.

DCF terms explained+

DCF (discounted cash flow) estimates how much cash the company will generate in the future and converts it into today's value per share.

Free cash flow (FCF) is the money left after running the business and investing. “12 m” means the last 12 months.

The discount rate expresses risk: the riskier the company, the higher the rate and the lower the fair value.

Fair value is a model estimate — not the market price and not an investment recommendation.

With Premium you can adjust growth, the discount rate and free cash flow, and the fair value recalculates live.

Adjust assumptions14 days free →

A model estimate, not an investment recommendation. Past performance does not guarantee future results.

§ Valuation check

Is the price reasonable?

Six quick tests: price against fair value, the last year, similar companies and analyst estimates. They are calculated from the numbers, not from AI estimates. This is not a recommendation.

Data 18 of 18

Valuation score

0/ 6

6/6 tests available

1. Below DCF fair value

15.6% above the DCF midpoint.

2. Well below DCF value

Discount = below the range or at least 15% below the midpoint.

3. Price vs. the last year

96% above the 1-year low (164.4 USD to 253.8 USD), based on stored daily prices.

4. P/E vs. similar companies

P/E 39.1 vs. median 26.4 (71 companies).

5. P/E relative to growth

PEG 2.3; a lower value means cheaper growth.

6. Analyst price target

-4.7% vs. the current price, 31 analysts.

Price vs DCF

Current price

249.9 USD

Low 171.9 USDHigh 278.8 USD

Current priceDCF midpoint: 216.2 USD

Price vs analyst target

Current price

249.9 USD

Low 175.0 USDHigh 300.0 USD

Current priceAverage: 238.2 USD

DCF gap

within range

The price is within the model range of 171.9 USD to 278.8 USD.

Analyst target

-4.7%

Average target 238.2 USD vs. price 249.9 USD.

Analyst consensus

Target range

175.0 USD - 300.0 USD

Coverage

31 analysts

Analyst consensus

1.9 / 5

Changes 180 d

+6 / -0

EPS next year

31.9%

Revenue next year

2.1%

Valuation multiples

39.1

13.3

1.7

3.2

11.8

2.3

52-week range96% above the low

164.4 USD253.8 USD

-85.0%

3.0%

8.3%

4.6%

Price vs 50D16.3%

Price vs 200D28.1%

Metrics explained+

Price and fair value

DCF range: A model estimate of fair value from future free cash flow. A price above the range means the market pays a premium over the model; a price below it may signal a more conservative market valuation or an overly optimistic model.
Analyst target: The average and range of the analyst price targets we track. It is the market consensus, not a FinSignal recommendation, and it can lag fast price moves.
52-week range: Shows where the current price sits between the low and high of the last year. A value near the high often signals strong momentum, but on its own says nothing about whether the stock is expensive.
Price vs 50D / 200D: Compares the price with its short- and long-term moving averages. A positive value means the price is above the trend; a negative one below it.

Multiples

P/E: Price relative to current earnings. A lower P/E can mean cheaper, but it can also point to a weak outlook or risk.
Forward P/E: Price relative to next year's expected earnings. For growing companies it is often more useful than the historical P/E because it reflects estimates of future earnings.
P/B: Price relative to the book value of equity. It makes more sense for banks, insurers and capital-intensive companies than for software or brands.
P/S: Price relative to revenue. It helps with companies that have low or negative earnings; a high P/S means the market expects strong growth or future margins.
EV/EBITDA: The value of the whole company, including debt, relative to operating profit before depreciation. Useful for comparing companies with different leverage.
PEG: P/E adjusted for earnings growth. A value around 1 may suggest the valuation matches growth, but the metric is sensitive to estimates.

Growth and quality

EPS growth: Year-on-year change in earnings per share. Strong growth supports a higher valuation, but for cyclical companies it can be temporary.
Revenue growth: The growth rate of sales. It helps tell whether profits grow on real demand or mainly on cost savings.
Net margin: How much of each unit of revenue is left as net profit. A higher margin often points to stronger pricing power or more efficient operations.
ROE: Return on equity. A high ROE can signal a quality business, but check that it is not artificially boosted by heavy debt.

Most data available. Missing values mean the market data source did not provide them for this ticker. The data is indicative and may be delayed. Price as of 26/10/2026.

Management and competitive advantage

Both are estimated by the AI from the company profile, news and results. They do not count towards the 6-pillar financial health score. The AI comments are in Czech.

strong

Management má vysoké skóre díky zkušenostem a dobré strategické orientaci, což podporuje stabilitu firmy.

good

Moat je silný díky značce a portfoliu patentovaných léčiv, i když konkurence v sektoru je vysoká.

Information

Type: Global stock
Symbol: BIIB
Exchange: NASDAQ
Currency: USD
Sector: Healthcare
: 39.1x
: 32.5B USD
: 44.3 %
: 0.17

§ Risk profile

Výsledky klinických studií nebo regulatorní rozhodnutí mohou rychle změnit očekávání ohledně budoucích tržeb. Českého investora navíc ovlivňuje kurz dolaru vůči koruně.

Ask the AI about Biogen Inc.All signals